Skip to main content

Table 3 The difference of prognostic factors between PFS (−) group and PFS(+) group

From: Effects of reduced platelet count on the prognosis for patients with non-small cell lung cancer treated with EGFR-TKI: a retrospective study

Values PFS (−) PFS (+) Statistic(χ2) P-value
N 5 47   
Platelet    0.653 0.390
 Increase 1(20%) 18(38.3%)   
 Decrease 4(80%) 29(61.7%)   
D-dimer    0.211 0.549
 Increase 1(20%) 14(29.8%)   
 Decrease 4(80%) 33(70.2%)   
Gender    0.221 0.500
 Male 2(40%) 24(51.1%)   
 Female 3(60%) 23(48.9%)   
Age    0.221 0.500
 ≥ 62.5 2(40%) 24(51.1%)   
  < 62.5 3(60%) 23(48.9%)   
Smoking    0.405 0.467
 Past/current 4(80%) 31(66.0%)   
 Never 1(20%) 16(34.0%)   
Exon21    2.038 0.153
 No 5(100%) 33(70.2%)   
 Yes 0(0%) 14(29.8%)   
Exon19    4.387 0.059
 No 5(100%) 24(51.1%)   
 Yes 0(0%) 23(48.9%)   
Other diseases    3.457 0.077
 No 5(100%) 27(57.4%)   
 Yes 0(0%) 20(42.6%)   
Other treatment     
 No 1(20%) 19(40.4%) 0.797 0.354
 Yes 4(80%) 28(59.6%)   
  1. PFS progression-free survival, PFS (+) progression group, PFS (−) No-progression group
\